LB Pharmaceuticals appoints Joseph Miller as CFO, effective September 2, 2026

LB PHARMACEUTICALS INC

Joseph M. Miller named CFO; previously CFO of Aurinia Pharmaceuticals (April 2020–March 2026).
Initial annual base salary of $530,000; target bonus of 40% of base salary.
Inducement option for 200,000 shares vesting over 4 years, 25% on first anniversary.
Company nears NOVA-2 clinical trial readout and prepares for potential LB-102 launch in schizophrenia.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joseph M. Miller

Chief Financial Officer

LBRX · LB PHARMACEUTICALS INC

Effective: 2026-09-02
Filed: September 3, 2026, 8:05 AM ET

On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph M. Miller was appointed as Chief Financial Officer at LB PHARMACEUTICALS INC.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026

View on SEC.gov

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-381076

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.